Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/immunol.1.004
Vaccine for leishmaniasis: New era of CRISPR generated Live attenuated dermotropic Leishmania
Kamaleshwar Singh1, Swarnendu Kaviraj1, Subir Karmakar1, Sanjay Singh1,*
- 1Vaccine Formulation and Research Center, Gennova Biopharmaceuticals Ltd., Pune, Maharashtra 411057, India
Corresponding Author
Sanjay Singh, Sanjay.Singh@gennova.co.in
Received Date: February 21, 2022
Accepted Date: March 21, 2022
Singh K, Kaviraj S, Karmakar S, Singh S. Vaccine for leishmaniasis: New era of CRISPR generated Live attenuated dermotropic Leishmania. J Cell Mol Immunol. 2022;1(1):12-16.
Copyright: © 2022 Singh K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Using CRISPR gene-editing technology, researchers have generated a live attenuated centrin gene deleted Leishmania major parasites (LmCen-/-) which are able to protect against visceral leishmaniasis caused by Leishmania donovani parasite. Since LmCen-/- vaccine is antibiotic resistant marker free, safe and prevents mortality, scientists are planning to use it in Phase I human clinical trials.
Keywords
Leishmania, Live attenuated Vaccine, centrin gene, Clinical trial, CRISPR
Recommended Articles
A scoping review of outcome measures in ovarian cancer clinical trials
The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.
Effect of pentoxifylline on the dose of erythropoietin among hemodialysis patients: A double-blind randomized clinical trial
Renal anemia is a major complication in chronic kidney disease (CKD), and is a problem that has yet to be overcome. This problem had been improved by the recombinant human erythropoietin (rhEPO), but some patients are relatively resistant to it and require higher doses, which is associated with increased adverse outcomes and mortality. Furthermore, the consequence of higher demand for rhEPO to achieve target Hb level is costly. Some factors can be considered as the reasons of rhEPO resistance; blood loss, impaired hematopoiesis and inadequate dialysis. Moreover, there is a hypothesis that enhancement of the immune system activity in CKD patients is one of the important causes of resistance to EPO, and the use of anti-inflammatory drugs like pentoxifylline (PTX) may be useful as a methylxanthine derivate used for the management of chronic peripheral arterial disease that increases the blood flow to the microcirculation because of its potent hemorheological properties, which include preservation of the erythrocyte water and cation content and enhanced tissue oxygenation.
Monitoring clinical trials in infectious diseases
In early 2020, the contagious and deadly virus, SARS-CoV-2, was identified. The virus spread rapidly worldwide and was declared a pandemic by the World Health Organization (WHO) in March of 2020 [1]. While many who became infected remained asymptomatic, an alarming number of infected individuals developed severe symptoms, often requiring hospitalization and intensive care, or resulting in death.
Real-world evidence corroborates the clinical trial results for management of HER2-positive metastatic breast cancer with T-DM1: a systematic review
Purpose: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab covalently linked to the cytotoxic agent DM1, is utilized for the management of human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (mBC), after progression on prior trastuzumab. Its regulatory approval preceded the era before pertuzumab approval.